Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Novartis
|
| gptkbp:activities |
IL-17 A inhibitor
|
| gptkbp:approves |
gptkb:FDA
gptkb:EMA |
| gptkbp:clinical_trial |
gptkb:FUTURE_3
Phase III FUTURE 1 FUTURE 2 MEASURE 1 MEASURE 2 active ankylosing spondylitis active psoriatic arthritis moderate to severe plaque psoriasis MEASURE 3 |
| gptkbp:competitors |
biologics for psoriasis
other IL-17 inhibitors |
| gptkbp:contraindication |
active tuberculosis
hypersensitivity to secukinumab serious infections |
| gptkbp:dosage_form |
solution for injection
|
| gptkbp:duration |
once a month
loading dose |
| gptkbp:effective_date |
January 2015
|
| gptkbp:formulation |
auto-injector
pre-filled syringe |
| https://www.w3.org/2000/01/rdf-schema#label |
Cosentyx
|
| gptkbp:ingredients |
gptkb:secukinumab
|
| gptkbp:invention |
2026
|
| gptkbp:is_monitored_by |
allergic reactions
infections liver function blood cell counts |
| gptkbp:is_used_for |
treatment of psoriasis
treatment of ankylosing spondylitis treatment of psoriatic arthritis |
| gptkbp:manager |
subcutaneous injection
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:population |
gptkb:Person
adults |
| gptkbp:price |
high
|
| gptkbp:requires |
gptkb:stock_market_index
|
| gptkbp:research_focus |
efficacy in different populations
long-term safety |
| gptkbp:scholarships |
gptkb:stock_market_index
|
| gptkbp:side_effect |
fatigue
headache nausea diarrhea increased risk of infections |
| gptkbp:storage |
refrigerated
|